ENTITY

ImmuPharma Plc (IMM LN)

4

Analysis

Health Care • United Kingdom

ImmuPharma plc, a pharmaceutical company, develops drug candidates based on peptide therapeutics to treat serious medical conditions. The company?s lead product candidates include the Lupuzor, which is in Phase III clinical trials for the treatment of lupus, a chronic, autoimmune, and inflammatory disease; IPP-204106, an anti-cancer nucleolin antagonis peptide program that has completed Phase I/IIa clinical trials to treat cancer; IPP-201007, which is in pre-clinical development stage for the treatment of inflammatory/allergic conditions, such as asthma and rheumatoid arthritis; IPP-102199 that is in pre-clinical development stage to treat moderate and severe pain; and IPP-203101, a peptide-based antibiotic, which is in pre-clinical development stage for the treatment of lethal infections, such as methicillin-resistant staphylococcus aureus and other hospital acquired infections. Its discovery pipeline includes heterocyclic ureas scaffolds; and peptide to drug converting technology, which enhances a peptide?s plasma half-life and efficacy. ImmuPharma plc has collaboration arrangements with the Centre National de la Recherch� Scientifique; and the Institut National de la Sante et de la Recherche Medicale. The company was founded in 1999 and is headquartered in London, the United Kingdom.

more

Refresh

Focused

bullish•Botswana Diamonds

•21 Mar 2025 11:27•Issuer-paid

Hybridan Small Cap Feast: 13/03/2025

The assessment has reached an advanced stage where eleven Prospecting Licenses have now been applied for, covering 7,322 square kilometres.

Hybridan

265 Views

Share

bullish•ONDO INSUR TECH

•14 Feb 2025 02:39•Issuer-paid

Hybridan Small Cap Feast: 13/02/2025

This proven innovation and expertise are now being applied to bespoke designs for the newly awarded pressure-door contract.

Hybridan

104 Views

Share

bullish•Oxford Nanopore Technologies

•11 Jan 2025 02:00•Issuer-paid

Hardman & Co Monthly: January 2025

Feature article: Hardman & Co Healthcare Index, 2024 – Tough year for Life Sciences By Dr Martin Hall The main function of the HHI is to...

Hardman & Co

397 Views

Share

bullish•Thematic (Sector/Industry)

•10 Jan 2025 22:18•Issuer-paid

Hardman & Co Healthcare Index: 2024 – Tough year for Life Sciences

The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments...

Hardman & Co

393 Views

Share

No more insights

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.53.10

x